ELELYSO Rx

Select the drug indication to add to your list

ELELYSO

Inborn errors of metabolism
Only 4 drugs may be compared at once

Generic Name and Formulations:

Taliglucerase alfa (recombinant) 200 Units; per vial; lyophilized pwd; for IV infusion after reconstitution; preservative-free.

Company:

Pfizer Inc.

Select therapeutic use:

Indications for ELELYSO:

Long-term enzyme replacement therapy (ERT) for patients with confirmed Type 1 Gaucher disease.

Adults and Children:

<4yrs: not established. Give by IV infusion over 60–120 minutes. ≥4yrs: 60 Units/kg once every 2 weeks. Begin treatment with Elelyso at the same dose when switching from imiglucerase.

Warnings/Precautions:

Have appropriate medical support available. Closely monitor patients during and after the infusion. Discontinue if anaphylaxis occurs and treat appropriately. Reduce or temporarily interrupt infusion, or administer antihistamines, corticosteroids and/or antipyretics if hypersensitivity reactions occur. Monitor for development of anti-drug antibodies. Pregnancy (Cat.B). Nursing mothers.

Pharmacological Class:

Lysosomal glucocerebroside-specific enzyme.

Adverse Reactions:

Headache, arthralgia, fatigue, nausea, dizziness, abdominal pain, pruritus, flushing, vomiting, urticaria, extremity pain.

Generic Availability:

NO

How Supplied:

Single-use vials—1

ELELYSO 200 units vials (Qty:1)

appx. price $814.00